Status:
COMPLETED
Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer
Lead Sponsor:
Centre Oscar Lambret
Conditions:
Esophageal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profil...
Detailed Description
Further informations will be provided by Centre Oscar Lambret.
Eligibility Criteria
Inclusion
- Invasive esophageal carcinoma at any stage (all T, N0 or N1, M0 or M1a), histologically proven
- Treated by exclusive concomitant radiochemotherapy
- Written informed consent
Exclusion
- Presence of a second uncontrolled cancer
- Metastatic carcinoma
- Metastatic disease, except cervical lymphnodes... (M1a)
- In situ carcinoma
- Eso-gastric junction cancer (Siewert II ou III)
- Inclusion in a clinical trial with an experimental drug during the study and until 15 weeks after the end of radiotherapy)
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00911092
Start Date
October 1 2007
End Date
December 1 2011
Last Update
January 2 2012
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Paul Papin
Angers, France, 49933
2
Centre Hospitalier Universitaire
Brest, France, 29200
3
Centre François BACLESSE
Caen, France, 14046
4
Centre Oscar Lambret
Lille, France, 59020